Literature DB >> 20457819

Intracellular concentrations of posaconazole in different compartments of peripheral blood.

Fedja Farowski1, Oliver A Cornely, Jörg J Vehreschild, Pia Hartmann, Tim Bauer, Angela Steinbach, Maria J G T Rüping, Carsten Müller.   

Abstract

Therapeutic drug monitoring (TDM) of antifungal plasma concentrations is increasingly recommended. However, data on antifungal concentrations in the other compartments of the peripheral blood are limited. Hence, we collected 23 blood samples from 14 patients receiving posaconazole for prophylaxis of fungal infections. These samples were separated by double-discontinuous Ficoll-Hypaque density gradient centrifugation. The intracellular posaconazole concentrations of the obtained cells, i.e., the peripheral blood mononuclear cells (PBMCs), polymorphonuclear leukocytes (PMNs), and red blood cells (RBCs), were determined by liquid chromatography-tandem mass spectrometry. The intracellular concentrations of the PBMCs and PMNs were significantly higher than those of surrounding media (P < 0.001). The ratios between the intracellular and extracellular concentrations (C/E) were 22.5 +/- 21.2, 7.66 +/- 6.50, and 0.09 +/- 0.05 for the PBMCs, PMNs, and RBCs, respectively. Posaconazole reaches high concentrations within human PBMCs and PMNs and is, to a lesser extent, present in RBCs. The high intracellular concentrations might contribute to posaconazole efficacy and distribution.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20457819      PMCID: PMC2897276          DOI: 10.1128/AAC.01407-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection.

Authors:  A J Ullmann; O A Cornely; A Burchardt; R Hachem; D P Kontoyiannis; K Töpelt; R Courtney; D Wexler; G Krishna; M Martinho; G Corcoran; I Raad
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

Review 2.  Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations.

Authors:  Jeannina Smith; David Andes
Journal:  Ther Drug Monit       Date:  2008-04       Impact factor: 3.681

Review 3.  Leukocyte-endothelial interactions.

Authors:  J M Harlan
Journal:  Blood       Date:  1985-03       Impact factor: 22.113

4.  Quantitation of azoles and echinocandins in compartments of peripheral blood by liquid chromatography-tandem mass spectrometry.

Authors:  Fedja Farowski; Oliver A Cornely; Jörg J Vehreschild; Pia Hartmann; Tim Bauer; Angela Steinbach; Maria J G T Rüping; Carsten Müller
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

5.  Uptake and intracellular activity of voriconazole in human polymorphonuclear leucocytes.

Authors:  Sofía Ballesta; Isabel García; Evelio J Perea; Alvaro Pascual
Journal:  J Antimicrob Chemother       Date:  2005-04-11       Impact factor: 5.790

6.  Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state.

Authors:  John E Conte; Jeffrey A Golden; Juliana Kipps; Marina McIver; Elisabeth Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

7.  Uptake and intracellular activity of fluconazole in human polymorphonuclear leukocytes.

Authors:  A Pascual; I García; C Conejo; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

8.  Posaconazole: a next-generation triazole antifungal.

Authors:  Fedja Farowski; Jörg J Vehreschild; Oliver A Cornely
Journal:  Future Microbiol       Date:  2007-06       Impact factor: 3.165

9.  Uptake of itraconazole by alveolar macrophages.

Authors:  J R Perfect; D V Savani; D T Durack
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

Review 10.  Therapeutic drug monitoring for triazoles.

Authors:  William W Hope; Eliane M Billaud; Jodie Lestner; David W Denning
Journal:  Curr Opin Infect Dis       Date:  2008-12       Impact factor: 4.915

View more
  17 in total

1.  Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome.

Authors:  J J Vehreschild; C Müller; F Farowski; M J G T Vehreschild; O A Cornely; U Fuhr; K-A Kreuzer; M Hallek; V Kohl
Journal:  Eur J Clin Pharmacol       Date:  2012-06       Impact factor: 2.953

2.  Relevance of timing for determination of posaconazole plasma concentrations.

Authors:  Werner J Heinz; Janina Zirkel; Anna Kuhn; Diana Schirmer; Ulrike Lenker; Daniela Keller; Hartwig Klinker
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

Review 3.  Beyond tissue concentrations: antifungal penetration at the site of infection.

Authors:  Yanan Zhao; Brendan Prideaux; Shane Baistrocchi; Donald C Sheppard; David S Perlin
Journal:  Med Mycol       Date:  2019-04-01       Impact factor: 4.076

4.  Intrapulmonary posaconazole penetration at the infection site in an immunosuppressed murine model of invasive pulmonary aspergillosis receiving oral prophylactic regimens.

Authors:  Seyedmojtaba Seyedmousavi; Roger J M Brüggemann; Willem J G Melchers; Paul E Verweij; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

5.  Understanding antifungal prophylaxis with posaconazole in hematology patients: an evolving bedside to bench story.

Authors:  Donald C Sheppard; Paolo Campoli; Rafael F Duarte
Journal:  Haematologica       Date:  2014-04       Impact factor: 9.941

6.  Posaconazole-Loaded Leukocytes as a Novel Treatment Strategy Targeting Invasive Pulmonary Aspergillosis.

Authors:  Shane R Baistrocchi; Mark J Lee; Melanie Lehoux; Benjamin Ralph; Brendan D Snarr; Robert Robitaille; Donald C Sheppard
Journal:  J Infect Dis       Date:  2017-06-01       Impact factor: 5.226

Review 7.  Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring.

Authors:  Michael J Dolton; John E Ray; Deborah Marriott; Andrew J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

8.  Pharmacokinetics of posaconazole within epithelial cells and fungi: insights into potential mechanisms of action during treatment and prophylaxis.

Authors:  Paolo Campoli; David S Perlin; Arnold S Kristof; Theodore C White; Scott G Filler; Donald C Sheppard
Journal:  J Infect Dis       Date:  2013-08-01       Impact factor: 5.226

9.  Posaconazole prophylaxis in experimental azole-resistant invasive pulmonary aspergillosis.

Authors:  Seyedmojtaba Seyedmousavi; Johan W Mouton; Willem J G Melchers; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

10.  High Intracellular Concentrations of Posaconazole Do Not Impact on Functional Capacities of Human Polymorphonuclear Neutrophils and Monocyte-Derived Macrophages In Vitro.

Authors:  Fedja Farowski; Oliver A Cornely; Pia Hartmann
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.